Novartis Pays Sironax $125M to Acquire Platform for Crossing the Blood-Brain Barrier
Deals·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.
Proceeds from the deal, which hands Novartis global rights to a technology.
NovartisSironax
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Proceeds from the deal, which hands Novartis global rights to a technology”
biopharma dive — Novartis to pay $125M for blood-brain barrier crossing platform“Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.”
fierce biotech — <a href="/biotech/novartis-pays-sironax-125m-acquire-platform-crossing-blood-brain-barrier" hreflang="en">Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier</a>